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therapeutic efficacy and side-effects of antipsychotic drugs. Brain-derived neurotrophic factor (BDNF) is a
neurotrophin that plays a major role in neurogenesis and neuroplasticity, and in the modulation of several
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antipsychotic drugs. The BDNF Val66Met polymorphism has been related to the pathophysiology of
schizophrenia, psychotic symptomatology, cognition, efficacy and side-effects of antipsychotic drugs. The
BDNF Val66Met variants could be a promising target for antipsychotic medication options or developing
next generation antipsychotic drugs. However, some studies showed inconsistent results due to sample size,
ethnic differences and different antipsychotic drugs. Further studies will be required in this area to confirm the
effect of the BDNF Val66Met polymorphism in the pathophysiology of schizophrenia and patients' response
to antipsychotic drugs, especially in a larger sample size and in different ethnic populations.
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Abstract   
Antipsychotic drugs remain the mainstay of pharmacotherapy for schizophrenia. As there are 
large individual variations in efficacy and side-effects of antipsychotic drugs, there is a strong 
demand for personalized medication to treat schizophrenia. Pharmacogenetic research into 
antipsychotic drugs has examined a number of genetic variants and only a few 
polymorphisms have been found which promise to be associated with the therapeutic efficacy 
and side-effects of antipsychotic drugs. Brain-derived neurotrophic factor (BDNF) is a 
neurotrophin that plays a major role in neurogenesis and neuroplasticity, and in the 
modulation of several neurotransmitter systems including the dopaminergic system involved 
in the pathophysiology of schizophrenia. This review focused on the association between the 
BDNF gene Val66Met polymorphism and antipsychotic drugs. The BDNF Val66Met 
polymorphism has been related to the pathophysiology of schizophrenia, psychotic 
symptomatology, cognition, efficacy and side-effects of antipsychotic drugs. The BDNF 
Val66Met variants could be a promising target for antipsychotic medication options or 
developing next generation antipsychotic drugs. However, some studies showed inconsistent 
results due to sample size, ethnic differences and different antipsychotic drugs. Further 
studies will be required in this area to confirm the effect of the BDNF Val66Met 
polymorphism in the pathophysiology of schizophrenia and patients’ response to 
antipsychotic drugs, especially in a larger sample size and in different ethnic populations.  
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Schizophrenia exhibits complex and serious symptoms which vary extensively between 
individuals. Antipsychotic drugs have remained the mainstay of pharmacotherapy for 
schizophrenia over the past 60 years. Antipsychotic drugs are generally divided into typical 
and atypical agents. Typical antipsychotics such as haloperidol mainly bind to dopamine D2 
receptors, which often cause extrapyramidal symptoms (EPS), and even irreversible tardive 
dyskinesia (TD) [1, 46]. Compared to typical antipsychotics, besides blockage of D2 
receptors, atypical antipsychotics including olanzapine and clozapine have more diverse 
receptor binding profiles such as the 5-HT2A and 5-HT2C receptors, which are less 
frequently accompanied by EPS and TD, but are often associated with side-effects such as 
obesity and other metabolic disorders [46]. Importantly, there are larger individual variations 
in the therapeutic efficacy and in the side-effects of antipsychotic drugs, while only about 
50% of patients treated with antipsychotic drugs present improvement in clinical symptoms 
[23]. Moreover, a study showed an average 74% (range from 64%-82% for different 
antipsychotic drugs) of schizophrenia patients discontinued their assigned medication within 
18 months, mainly due to their lack of efficacy and intolerable side-effects [21].  
 
Family and twin studies suggest that individual differences in schizophrenia patients in 
symptoms, therapeutic response and side-effects of antipsychotic drugs are significantly 
related to genetic differences. Therefore, the pharmacogenetics of antipsychotic drugs may 
provide important evidence that genetic variation influences patients’ response and 
intolerance to antipsychotic drugs. However, although the pharmacogenetics of antipsychotic 
drugs in dopamine and serotonin receptors such as D2, D3, 5-HT2A, and 5-HT2C receptors,  





findings [49], current results are still long away from explaining the individual variations in 
therapeutic responses, and side-effects of antipsychotic drugs.  
 
Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family of growth 
factors [40]. BDNF is the most widely distributed neurotrophin in the central nervous system, 
especially in the prefrontal cortex (PFC), hippocampus and hypothalamus, and plays critical 
roles in brain neurodevelopment, and maintenance of functional neurons and synaptic 
plasticity [40]. Decreased serum BDNF levels have been found in both first-episode and 
chronic schizophrenia patients [37, 39]. Serum BDNF  levels have been shown to be 
positively correlated with positive symptoms and negatively correlated with negative 
symptoms of schizophrenia [37, 39]. BDNF protein expression has been found to be reduced 
not only in blood serum but also cerebrospinal fluid (CSF) in both acute and chronic 
schizophrenia patients [37, 50]. Reduced expression of BDNF and its highly affiliated 
tropomyosin receptor kinase B (TrkB) have been found in the PFC and hippocampus of 
schizophrenia patients [30]. Thus BDNF should be a valuable candidate gene for 
pharmacogenetic analysis of antipsychotic drugs. 
 
The BDNF gene is located on chromosome 11p13. Several investigations into the role of 
BDNF gene polymorphisms have been conducted to establish both the efficacy and side-
effects of antipsychotics, and have had mixed outcomes [18, 25, 48]. The BDNF gene 
Val66Met (rs6265) polymorphism, which results in methionine (Met) substitution for valine 
(Val) at codon 66 in the 5’ pro-region of the gene, is a common functional single nucleotide 
polymorphism (SNP) of BDNF. This review is mainly focused on the BDNF gene Val66Met 





BDNF gene could be worth prioritising for pharmacogenetics’ research into antipsychotic 
drugs and its potential relevance to their treatment response and side-effects.    
 
2. BDNF Val66Met polymorphism and clinical and pathophysiological characteristics of 
schizophrenia 
In spite of some inconsistent findings about the association between BDNF Val66Met 
polymorphism and schizophrenia [13, 44], the BDNF Val66Met polymorphism has been 
found to be significantly associated with several clinical and pathophysiological 
characteristics of the illness, such as age of onset, symptoms and brain pathology [19, 28]. 
While the frequency of the Met/Met genotype in schizophrenia was significantly higher in 
those patients presenting mainly positive symptoms compared to those with negative 
symptoms [34], a recent study showed a significant association between the Val66Met 
polymorphism and negative symptoms severity in first episode schizophrenia spectrum 
disorders [24]. Schizophrenia patients carrying the BDNF Met/Met genotype have more 
delusional symptoms than 66Val allele carriers [15]. Schizophrenia patients who carry the 
BDNF Val/Met genotype had higher scores on a hallucinatory behaviour item than those with 
other genotypes [34]. An association between the BDNF Val66Met polymorphism and 
obsessive-compulsive symptoms has also been found in Egyptian schizophrenia patients [16].  
A Met carrier of the BDNF Val66Met genotype is associated with lower serum BDNF levels 
[43]. While the BDNF Val66Met polymorphism is not associated with hippocampal volume 
change over time in schizophrenia patients, there are smaller hippocampal volumes in 
patients homozygous for the Val allele compared to healthy Val homozygotes [20].  
 
It should be pointed out that some associations between the BDNF Val66Met and clinical and 





results are difficult to explain. For example, schizophrenia patients carrying the BDNF 
Met/Met genotype had a lower age of onset compared to those with Val/Val or Val/Met 
genotypes in an Armenian population [44]. However, another study found that schizophrenia 
patients with the Val/Met genotype had an earlier onset age than those with other genotypes 
in a Polish population [34]. These inconsistent findings between the BDNF Val66Met 
polymorphism and age at onset of schizophrenia may be attributed to ethnic difference, which 
warrants further investigation in a larger sample or different ethnic populations.  
 
3. BDNF Val66Met polymorphism and cognitive deficits  
Cognitive deficits are the core and enduring feature of schizophrenia, and include impairment 
of learning, memory, attention and cognitive processing speed. Neuroimaging studies have 
documented that the hippocampus plays a crucial role in these important cognitive functions 
[3]. Serum BDNF levels were identified to be associated with reductions in hippocampal 
volume in first-episode and drug-naive schizophrenic patients [31]. Generally, it is thought 
that typical antipsychotics are related to cognitive deterioration and atypical antipsychotics 
are associated with statistically significant but small improvements in cognition in 
schizophrenia patient treatments. However, high dose of atypical antipsychotics (e.g. 5-6 mg 
risperidone equivalents per day) may be associated with poorer cognitive performance in 
schizophrenia patients [10]. Importantly, BDNF serum levels are decreased and positively 
correlated with cognitive deficits in schizophrenia patients [51]. A recent study has found that 
olanzapine improves cognition especially for attention and immediate memory, which 
parallels increased plasma BDNF levels in acute onset of schizophrenia patients [54]. 
However, chronic treatment of olanzapine could cause metabolic syndrome in some (~44%) 
schizophrenia patients correlated significantly with cognitive impairment, in which these 





suggesting an interactive role of BDNF in the metabolic side-effects of olanzapine on 
cognitive function [45]. 
 
It is interesting that the BDNF Met variant is related to poor visuospatial and attention 
impairment in schizophrenia patients [41]. BDNF Val/Val genotype carriers showed better 
working memory than Val/Met and Met/Met genotype carriers in schizophrenia patients [32]. 
These findings supported that the BDNF Val66Met polymorphism might be significantly 
involved in the cognitive deficits of schizophrenia. On the other hand, carriers of the Met 
BDNF polymorphism exhibit cognitive deficits in episodic memory and abnormal 
hippocampal activation which commonly leads to cognitive dysfunction in both healthy 
populations and schizophrenia patients [9, 36]. However, another study reported that the 
66Met allele did not affect episodic memory in schizophrenia patients [7]. Although there are 
still some controversies, the BDNF Val66Met may be a new target to consider in developing 
new generation antipsychotic drugs for improving cognitive deficits for schizophrenia 
treatment.  
 
4. BDNF Val66Met polymorphism and efficacy of antipsychotic drugs   
BDNF modulates the major neurotransmitter systems including the dopaminergic, 
glutamatergic, and serotonergic systems [14, 28, 49]. It is well known that dopamine D2 
receptor antagonism is a unifying property of all antipsychotic drugs. Olanzapine treatment 
improves the reduced BDNF serum levels in first-episode or acute onset schizophrenia 
patients [12, 54]. Therefore, BDNF is significantly involved in the effects of antipsychotic 






Importantly, the BDNF Val/Val genotype and Val allele were found to be over-represented in 
the responder group compared to the non-responder group with various antipsychotic 
treatments including clozapine, olanzapine and others (Table 1) [42]. The BDNF Val/Val 
genotype was observed more frequently in treatment responders to olanzapine compared to 
other antipsychotic drugs including clozapine treatment, and this genotype was associated 
with an improvement in clinical symptoms (Table 1) [29]. Moreover, better treatment 
response to olanzapine was also associated with higher plasma BDNF levels in the Val/Val 
homozygous genotype in schizophrenia patients [27]. The potential mechanism of increased 
response to antipsychotic drugs of the BDNF Val/Val genotype and Val allele group is not 
clear. However, a study has shown that the BDNF Met allele may affect intracellular 
distribution, packaging, and release of BDNF protein [9]. Also, the BDNF Val/Val genotype 
is association with an increased synaptic plasticity and increased activity-dependent BDNF 
release [9]. Therefore, we hypothesise that the BDNF Val/Val genotype or Val allele in 
schizophrenia patients may show a better response to antipsychotic drugs, particularly 
olanzapine, by increased BDNF release and synaptic plasticity.  
 
Although studies support that the BDNF Val66Met variants may be significantly involved in 
the therapeutic response to antipsychotic drugs in schizophrenia treatment, there are a series 
of inconsistent findings (Table 1). For example, one study showed that there were no 
significant differences in therapeutic response to clozapine treatment among the three 
Val66Met-genotype subgroups in schizophrenia patients [17]. There is a greater incidence of 
the BDNF Met/Met genotype in patients with treatment resistant response to typical 
antipsychotics in the Caucasian population [47], however another study found a lack of 
association between the BDNF Val66Met polymorphism and patients’ response to typical 





polymorphism in antipsychotic drugs need to be further confirmed in schizophrenia treatment 
especially in different ethnic populations, a larger sample size and different antipsychotic 
drugs.  
 
5. BDNF Val66Met polymorphism and metabolic disorders  
Metabolic disorders such as weight gain, insulin resistance and diabetes are common and 
serious side-effects of antipsychotics, especially for atypical antipsychotic drugs [6, 8]. A 
recent meta-analysis in 25 studies with 154,718 schizophrenia and 4,343,407 control subjects 
showed antipsychotic treatment led to 2.5 times higher risk of type 2 diabetes (T2D) [33]. 
Several lines of evidence support that BDNF Met66 polymorphism is an essential contributor 
to the regulation of food intake, body weight gain and other metabolic disorders. For 
example, a meta-analysis showed that the BDNF Met66 allele increases the risk for eating 
disorders by 36% in bulimia nervosa or binge eating disorders [26].  The BDNF Val66Met is 
associated with not only obesity but also T2D [35]. A recent study showed that the BDNF 
Val66Met is positively associated with high BMI in schizophrenia patients, while bipolar 
disorder subjects with Met66Met genotype showed increase in the triglycerides/high-density 
(HDL) cholesterol ratio, a key marker for metabolic syndrome related to insulin resistance 
[4]. 
 
Importantly, BDNF Met variants were found to be significantly associated with obesity, 
weight gain and lipid metabolic disorders for schizophrenia patients treated with 
antipsychotic drugs (Table 1) [4, 53], while this weight gain side-effects of antipsychotic 
drugs in schizophrenia patients was also observed for the two-marker haplotype of BDNF 
across Val66Met and rs1519480 [42]. The BDNF Met allele was associated with increased 





with atypical antipsychotics, which suggests that glucose regulation is more dependent on 
genetic factors like the BDNF gene in schizophrenia patients (Table 1) [5]. These results 
provide supporting evidence that the BDNF Val66Met plays a significant role in metabolic 
disorders for schizophrenia patients treated with antipsychotic drugs. However, how the 
BDNF Val66Met affect BDNF activity and leads to metabolic disorders is not well known. 
Whether the BDNF 66Met allele has a significant impact on intracellular trafficking and 
activity-dependent secretion of BDNF in brain region-specific manner need further 
investigation, especially in  hypothalamic nuclei associated with eating behaviour, food 
consumption, and control of body weight [9]. Moreover, a study showed that BDNF 
Met66Met genotype has a strong relationship with BMI gain in male but not female 
schizophrenia patients [53]. Therefore, the effects of BDNF Val66Met on metabolic disorders 
induced by antipsychotics are needed for further investigations, especially longitudinal 
studies with larger sample sizes in schizophrenia patients.   
 
In addition, as discussion as above, the BDNF Val66Met might be involved in the aetiology 
and pathophysiology of both schizophrenia and metabolic disorder [13, 26, 35, 44]. 
Schizophrenia patients are also observed to have a higher morbidity of metabolic disorders 
than the general population although this might be partly due to antipsychotic treatment [11]. 
Further investigation is necessary to reveal whether the co-morbidity link between the two 
diseases are influenced by shared BDNF genetic variants, especially BDNF Val66Met, via the 
pleiotropic effects (i.e., the same DNA sequence causes the psychopathology inherent in 
schizophrenia and altered glucose metabolism).  
 





EPS including acute dystonia, akathisia and TD are normal and serious side-effects caused by 
antipsychotic drugs. Acute EPS are one of the main causes of noncompliance with 
antipsychotic treatment, while TD has the most serious impact on quality of life for 
schizophrenia patients. TD is a motor system disorder and potentially irreversible side-effect 
that is characterised by repetitive and involuntary movements experienced by about 20-50% 
of patients treated with long-term antipsychotic drugs, especially for typical antipsychotics 
[38]. Serum BDNF levels are lower in schizophrenia patients with TD compared to those 
without TD [52]. BDNF is found to increase the functions of the nigrostriatal dopaminergic 
system, a brain region implicated in the pathogenesis of TD and a major target area for 
antipsychotics. Therefore, BDNF may be involved in TD caused by treatment of 
schizophrenia with antipsychotics, especially for typical antipsychotics.  
 
A meta-analysis and other studies showed that Caucasian BDNF Met allele carriers had 
significantly higher TD occurrence than Asian patients treated with antipsychotics [18,22, 
25]. In addition, a Chinese population study indicated that the BDNF gene Val66Met 
polymorphism did not contribute to genetic susceptibility to TD or its severity [52]. However, 
treatment with Ginkgo biloba improved TD significantly more in the BDNF genotype of 
Val/Val than in the Val/Met or Met/Met genotypes in schizophrenia patients [52]. Another 
ethnic Chinese study showed that the BDNF val66met polymorphism did not play a 
significant role in the susceptibility to TD of chronic antipsychotic treatment, but exerted its 
effect on the clinically phenotypic variability in persistent TD patients [22]. These results 
support that the BDNF Val66Met polymorphism might be involved in TD after antipsychotic 
treatments in schizophrenia patients especially for the Caucasian populations. However, it is 
important to point out that a smaller number of Caucasian patients (19.5% compared to 





Val66Met polymorphism and TD [25]. Further studies in an extend sample size are needed 
for confirming the association between BDNF Val66Met variants and antipsychotic-induced 
TD in schizophrenia patients, particularly in Caucasian population.  
 
Conclusion 
Schizophrenia patients have large individual differences in clinical symptoms and response to 
antipsychotic drugs. Therefore, personalized medications are required in schizophrenia 
treatment. This review has provided evidence that the BDNF Val66Met polymorphism is 
significantly associated with the pathophysiology of schizophrenia, psychotic 
symptomatology, cognition, efficacy and side-effects of antipsychotic drugs. The BDNF 
Val66Met variants should be considered as a pharmacogenetic target for antipsychotic drugs 
or developing the next generation of antipsychotic drugs. However, there are some 
inconsistent findings in the association between the BDNF Val66Met polymorphism, clinical 
symptoms or response to antipsychotic drugs in schizophrenia treatment which needs further 
confirmation, especially in a larger sample size and in different ethnic populations. 
Furthermore, the associations between other BDNF genetic variants and response to 
antipsychotic drugs in schizophrenia patient are also necessary to be investigated.   
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